NCT03309605View on ClinicalTrials.gov

Phase 1 Study of ELX-02 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 11, 2017

Primary Completion Date

June 17, 2019

Study Completion Date

July 17, 2019

Conditions
Genetic DiseaseNonsense Mutation
Interventions
DRUG

ELX-02

ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

SGS Life Sciences, Clinical Pharmacology Unit, Antwerp

Sponsors
All Listed Sponsors
collaborator

SGS Life Sciences, a division of SGS Belgium NV

OTHER

lead

Eloxx Pharmaceuticals, Inc.

INDUSTRY

NCT03309605 - Phase 1 Study of ELX-02 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter